UNSPSC 51263142: Flestolol

This classification denotes a beta-adrenergic blocking agent with the molecular formula C15H22FN3O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier LI02075E1W, chemically known as [3-[[1-(carbamoylamino)-2-methylpropan-2-yl]amino]-2-hydroxypropyl]2-fluorobenzoate but generally known as flestolol, which bears US NIH Compound Identifier 55885. European Medicines Agency schedules flestolol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07641MIG.

Most nations schedule flestolol under HS 29242190 and SITC 51473. As of Q4 2014, FLESTOLOL remains the US FDA Preferred Term for this commodity. Flestolol bears US NLM identifiers UMLS ID C0060455 and NCI Concept Code C72784. SMILES: CC(C)(CNC(=O)N)NCC(COC(=O)C1=CC=CC=C1F)O.

UNSPSC 51263142 Flestolol is a Commodity code under which state and local governments procure pharmaceutical products and drug management systems, though the recent solicitations under this code show little direct alignment with the code's nominal scope. The two recent opportunities tagged to this code actually reflect acquisitions of naloxone (an opioid antagonist) and safe drug deactivation systems on one hand, and exploratory market research into direct-to-manufacturer pharmacy benefit program models on the other. State and local issuing bodies using this code include county health departments and state health and human services agencies; Seminole County, Florida and the Texas Health and Human Services Commission are the visible recent buyers.

Seminole County, Florida posted an IFB on June 30, 2026 (due July 26, 2023) to procure 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building in Sanford, with a two-year initial term and one-year renewal option. The Texas Health and Human Services Commission issued a Request for Information on April 3, 2026 to gather vendor capabilities and market intelligence on direct-to-manufacturer prescription fulfillment models for a Therapeutic Pharmacy Initiative program, seeking vendor experience with direct contracting, negotiated net pricing, and value-based agreements outside traditional pharmacy benefit manager and group purchasing organization channels. The code shows minimal recent activity outside these two solicitations, and the scope mismatch between the nominal code name and the actual work being bought suggests this code may not be the primary vehicle for state and local pharmaceutical procurement in most jurisdictions.